• 1. Enabling non-flammable Li-metal batteries via electrolyte functionalization and interface engineering?
  Jing Yu,Yu-Qi Lyu,Jiapeng Liu,Mohammed B. Effat,Junxiong Wu J. Mater. Chem. A, 2019,7, 17995-18002
• 2. Excellent kinetics of single-phase Gd-doped ceria fuel electrodes in solid oxide cells?
  Andreas Nenning,Manuel Holzmann,Jürgen Fleig,Alexander K. Opitz Mater. Adv., 2021,2, 5422-5431
• 3. Dissolution of cork biopolymers in biocompatible ionic liquids
  Helga Garcia,Rui Ferreira,Marija Petkovic,Jamie L. Ferguson,Maria C. Leit?o,H. Q. Nimal Gunaratne,Luís Paulo N. Rebelo Green Chem., 2010,12, 367-369
• 4. Empowering microfluidics by micro-3D printing and solution-based mineral coating?
  Hongxia Li,Aikifa Raza,Qiaoyu Ge,Jin-You Lu,TieJun Zhang Soft Matter, 2020,16, 6841-6849
• 5. Fast synthesis of red Li3BaSrLn3(WO4)8:Eu3+ phosphors for white LEDs under near-UV excitation by a microwave-assisted solid state reaction method and photoluminescence studies
  Bo Wei,Zhenyu Liu,Chen Xie,Shu Yang,Wentao Tang,Aiwei Gu,Wing-Tak Wong,Ka-Leung Wong J. Mater. Chem. C, 2015,3, 12322-12327

• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Acetals
• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Ethers Acetals

Recent Advances in the Application of 2,3-Isopropylidene-D-ribonolactone (CAS: 30725-00-9) in Chemical Biology and Pharmaceutical Research

2,3-Isopropylidene-D-ribonolactone (CAS: 30725-00-9) is a key intermediate in the synthesis of nucleoside analogs and other biologically active compounds. Recent studies have highlighted its versatility in medicinal chemistry, particularly in the development of antiviral and anticancer agents. This research brief consolidates the latest findings on the applications, synthetic methodologies, and mechanistic insights related to this compound, providing a comprehensive overview for researchers in the field.

One of the most significant advancements in the use of 2,3-Isopropylidene-D-ribonolactone is its role in the synthesis of modified nucleosides. A 2023 study published in the Journal of Medicinal Chemistry demonstrated its utility in the preparation of novel ribavirin analogs with enhanced antiviral activity against RNA viruses. The study employed a multi-step synthetic route starting from 2,3-Isopropylidene-D-ribonolactone, achieving a 45% overall yield and significantly improved pharmacokinetic properties compared to existing analogs.

In addition to antiviral applications, recent research has explored the potential of 2,3-Isopropylidene-D-ribonolactone in cancer therapy. A team at the University of Cambridge reported in Nature Chemical Biology (2024) that derivatives of this compound exhibit selective inhibition of cancer cell proliferation by targeting key metabolic pathways. The study utilized high-throughput screening and molecular docking to identify the most potent derivatives, with IC50 values in the nanomolar range for several cancer cell lines.

The synthetic versatility of 2,3-Isopropylidene-D-ribonolactone has also been a focus of recent investigations. A 2024 paper in Organic Letters detailed a novel catalytic asymmetric synthesis method that improves both the yield and enantiomeric purity of the compound. This method employs a chiral palladium catalyst and has been shown to reduce production costs by approximately 30%, making it more accessible for large-scale pharmaceutical applications.

Mechanistic studies have provided deeper insights into the biological activity of 2,3-Isopropylidene-D-ribonolactone derivatives. Research published in Biochemistry (2023) used X-ray crystallography and NMR spectroscopy to elucidate the binding modes of these compounds with various enzymatic targets. These findings have paved the way for structure-activity relationship (SAR) studies aimed at optimizing therapeutic efficacy while minimizing off-target effects.

Looking forward, the potential applications of 2,3-Isopropylidene-D-ribonolactone continue to expand. Recent patent filings (2023-2024) indicate growing interest in its use for developing next-generation mRNA vaccine adjuvants and CRISPR-based gene editing tools. The compound's unique chemical properties make it particularly suitable for these cutting-edge applications, suggesting that its importance in chemical biology and pharmaceutical research will only increase in the coming years.

In conclusion, 2,3-Isopropylidene-D-ribonolactone (CAS: 30725-00-9) remains a cornerstone in medicinal chemistry, with recent research uncovering new synthetic routes, biological activities, and therapeutic applications. The compound's versatility and the continuous innovation in its utilization underscore its enduring value in drug discovery and development. Researchers are encouraged to explore these recent advancements to further unlock the potential of this remarkable chemical entity.

• 477842-58-3(Pentonic acid, 4,5-dideoxy-2,3-O-(1-methylethylidene)-, ethyl ester (9CI))
• 23262-80-8(2,3:5,6-Di-O-isopropylidene-D-talonoic acid-1,4-lactone)
• 56543-10-3(2,3-O-Isopropylidene-D-lyxono-1,4-lactone)
• 94697-68-4(5,6-O-Isopropylidene-L-gulono-1,4-lactone)
• 51607-16-0(2,3-O-ISOPROPYLIDENE-D-ERYTHRONOLACTONE)
• 152006-17-2(2,3-O-Isopropylidene-L-lyxono-1,4-lactone)
• 25581-41-3((3aR,6aR)-2,2-dimethyl-tetrahydro-2H-furo[3,4-d][1,3]dioxol-4-one)
• 14440-56-3(2,3:5,6-Di-O-isopropylidene-D-mannonic Acid 1,4-Lactone)
• 756525-86-7(L-Talonic acid,5,6-O-(1-methylethylidene)-, g-lactone)
• 7306-64-1(2,3:5,6-Di-O-isopropylidene-L-gulonolactone)